Video
Factors linked to increased likelihood of germline mutations in renal cell carcinoma
Author(s):
“We saw that with each additional enrichment feature the odds of finding a germline mutation would double,” says Alexis Rompré-Brodeur, MD.
Video Player is loading.
Alexis Rompré-Brodeur, MD, a urologic oncologist at McGill University discusses results of the study, “Germline testing in renal cell carcinoma: can enrichment features help predict germline alterations?” which he presented at the 2022 AUA Annual Meeting (PD18-10).
Related Videos
Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
Paul Sieber, MD, on the future of genetic testing in prostate cancer
Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
Tim Richardson, MD, on genetic testing in the era of targeted therapies
Discussing germline testing for prostate cancer with veterans
Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
Germline testing study’s implications for veteran access to prostate cancer treatments
Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
Daniel Kwon, MD, on germline testing for prostate cancer in veterans with service-connected benefits
Related Content
